Literature DB >> 3127710

Withdrawal of anticonvulsant drugs in patients free of seizures for two years. A prospective study.

N Callaghan1, A Garrett, T Goggin.   

Abstract

We discontinued anticonvulsant drugs in 92 patients who had been free of seizures during two years of treatment with a single drug. All the patients had epilepsy that had previously been untreated, and had been randomly assigned to receive carbamazepine, phenytoin, or sodium valproate. Thirty-one patients relapsed, and 61 remained free of seizures. The mean duration of the follow-up in the patients remaining free of seizures was 35 months (range, 6 to 62). There was no significant difference between the relapse rate among adults (35 percent) and that among children (31 percent). Our results suggest that the number of seizures a patient had before control was achieved, the number of drugs tried as single-drug therapy, and the type of treatment withdrawn all influenced the outcome. Among the various types of seizures, complex partial seizures with secondary generalization carried the worst prognosis. In comparison, the risk of relapse was 65 percent lower in patients with generalized seizures and 97 percent lower in patients with complex or simple partial seizures in the absence of secondary generalized attacks. Among the four electroencephalographic classes, class 4 (abnormal before treatment and unchanged before withdrawal) carried the worst prognosis. The risk of relapse was 94 to 99 percent lower in patients in the other three electroencephalographic classes. Among the three anticonvulsants, withdrawal of sodium valproate carried the worst prognosis. In comparison, the odds of relapsing were 28 percent lower after withdrawal of phenytoin and 85 percent lower after withdrawal of carbamazepine. We conclude that withdrawal of anticonvulsant medication should be considered in patients free of seizures for two years.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3127710     DOI: 10.1056/NEJM198804143181502

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  24 in total

Review 1.  Therapeutic drug monitoring of phenytoin. Rationale and current status.

Authors:  M Levine; T Chang
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 2.  Clinical symptoms, diagnosis, and treatment of neurocysticercosis.

Authors:  Hector H Garcia; Theodore E Nash; Oscar H Del Brutto
Journal:  Lancet Neurol       Date:  2014-11-10       Impact factor: 44.182

Review 3.  Care of the pregnant patient with medical illness.

Authors:  J L Carson; D L Elliot
Journal:  J Gen Intern Med       Date:  1988 Nov-Dec       Impact factor: 5.128

4.  The value of therapeutic drug monitoring to the practising physician--an hypothesis in need of testing.

Authors:  G T McInnes
Journal:  Br J Clin Pharmacol       Date:  1989-03       Impact factor: 4.335

Review 5.  The risks and benefits of withdrawing antiepileptic therapy.

Authors:  B Scherokman; B Jabbari
Journal:  Drug Saf       Date:  1993-06       Impact factor: 5.606

Review 6.  Seizure prophylaxis for brain tumour patients. Brief review and guide for family physicians.

Authors:  C B Agbi; M Bernstein
Journal:  Can Fam Physician       Date:  1993-05       Impact factor: 3.275

7.  Stopping antiepileptic drugs: when and why?

Authors:  John D Hixson
Journal:  Curr Treat Options Neurol       Date:  2010-06-26       Impact factor: 3.598

Review 8.  Driving and Epilepsy: a Review of Important Issues.

Authors:  Joon Y Kang; Scott Mintzer
Journal:  Curr Neurol Neurosci Rep       Date:  2016-09       Impact factor: 5.081

9.  Discontinuation of anti-epileptic therapy: a retrospective study of 86 children and adolescents.

Authors:  A Matricardi; F Bertamino; D Risso
Journal:  Ital J Neurol Sci       Date:  1995-12

10.  The value of routine electroencephalographic recordings in predicting postoperative seizures associated with meningioma surgery.

Authors:  Ralf D Rothoerl; D Bernreuther; C Woertgen; A Brawanski
Journal:  Neurosurg Rev       Date:  2002-10-10       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.